0.5 ml semaglutide PEPTIDE VIAL – UMBRELLA Labs Semaglutide Injection 0.50 mg/0.5 ml

Description

Compounding Pharmacy Economics Compounded Medication Costs: Raw Materials: Pharmaceutical-grade tirzepatide (API) Purchased from legitimate suppliers No development costs (existing drug) Cost: ~$65-100 per maximum dose Compounding Labor: Licensed pharmacists preparing medication Sterile compounding cleanroom USP Chapter 797 compliance Quality control testing Labor cost: ~$30-50 per patient/month Facility & Operations: FDA-registered compounding pharmacy Sterile cleanroom maintenance Equipment and supplies State pharmacy licensing Regulatory compliance Allocated cost: ~$40-60 per patient/month Quality Control: Sterility testing Potency verification Beyond-use date establishment Documentation Cost: ~$20-30 per patient/month Overhead: Pharmacy staff salaries Utilities and rent Insurance and licensing Technology systems Allocated cost: ~$30-50 per patient/month Total Compounding Cost: ~$185-290 per patient/month Telehealth Provider Markup: Medical oversight: ~$50-100/month Technology platform: ~$20-40/month Customer support: ~$20-40/month Profit margin: ~$40-170/month Final Price: $349-699/month What Compounding Eliminates No R&D Costs: Tirzepatide already developed by Eli Lilly Clinical trials completed FDA approval achieved Compounders use existing knowledge No Marketing Costs: Minimal advertising Word-of-mouth and organic growth No sales force No TV commercials No Complex Distribution: Direct from pharmacy to patient No PBM middlemen No rebate system No wholesaler markup Lower Profit Expectations: Smaller companies No public shareholders No Wall Street pressure Sustainable margins vs maximum extraction Result: 67-80% lower price for identical active ingredient

The MHRA Early Access to Medicines Scheme (EAMS) , which allows patients with life-threatening or seriously debilitating conditions to access promising unlicensed medicines before marketing authorisation